Loading
A phase 2 trial of niraparib and ipilimumab in pancreatic cancer, run by Abramson Cancer Center at Penn Medicine, now recruiting.
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy is a phase 2, randomised interventional study registered as NCT06747845 by Abramson Cancer Center at Penn Medicine, with a registry enrolment figure of 68 participants, started 2025-05-07 and due to reach its primary completion in 2028-06. Interventions recorded: Niraparib; FOLFIRI; Ipilimumab. Conditions listed: Pancreatic Adenocarcinoma Metastatic. Primary outcome: Progression-free survival (PFS) in the experimental arm. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Ipilimumab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares PARP inhibitors, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.